Lung cancer risk (17 studies) · Participants in trials with low risk of bias
Highest showed no clear difference in lung cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Breast cancer risk (14 studies) · Participants in trials with low risk of bias
Highest showed no clear difference in breast cancer risk No. of participants: 802 (1 RCT) compared with lowest selenium exposure (moderate certainty).
1 finding from 1 review
Bladder cancer risk No. of participants: 19,009 (2 RCTs) · Participants in trials with low risk of bias
Highest showed no clear difference in bladder cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Prostate cancer risk (13 studies) · Participants in trials with low risk of bias
Highest showed no clear difference in prostate cancer risk No. of participants: 18,942 (4 RCTs) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Any cancer risk No. of participants: 76,239 (7 observational studies) · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes any cancer risk No. of participants: 76,239 (7 observational studies) compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · proliferative diabetic retinopathy
0.5 may leads to lower BCVA: loss of 15 or more EDTRS letters ‐ 1 year compared with 0.1 second exposure (low certainty).
1 finding from 1 review
BCVA: gain of 15 or more ETDRS letters · proliferative diabetic retinopathy
0.5 showed no clear difference in BCVA: gain of 15 or more EDTRS letters ‐ 1 year compared with 0.1 second exposure (low certainty).
1 finding from 1 review
Progression of PDR · proliferative diabetic retinopathy
It is very uncertain whether 0.5 changes progression of PDR ‐ 1 year compared with 0.1 second exposure (very low certainty).
1 finding from 1 review
Regression of PDR · proliferative diabetic retinopathy
0.5 showed no clear difference in regression of PDR ‐ 1 year compared with 0.1 second exposure (low certainty).
1 finding from 1 review
Pain during laser treatment ‐ not reported · proliferative diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · proliferative diabetic retinopathy
1 finding from 1 review
Intervention not reported
Immediate change in level in year 2000 (noise level at work as PEL dose in dB(A); range 0 to 6400, log scale) · workers with noise exposure
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Change in slope after introduction (noise level at work as PEL dose in dB(A); range 0 to 6400, log scale) · workers with noise exposure
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Improvement in nutritional intake · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Healing of osteonecrosis - improvement ('healed' or 'improved' vs 'unchanged' or 'worse') · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse events · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Improvement of pre-existing accompanying symptoms other than pain · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Health economic measures · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Quality of life · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Pain · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found